Wedbush Morning Call - May 18 2026 6:59AM

Research evidence excerpt

Wedbush Morning Call - May 18 2026 6:59AM

fusp holding disease-modifying potential in FA.

Solid Biosciences Inc. (SLDB)

Rating: OUTPERFORM, 12-Month Price Target: $16.00, Price: $7.38

RGNX Read Through: RGX-202 Pivotal Data Bodes Well For SLDB's SGT-003 in DMD

The Wedbush View: Remain Outperform rated on SLDB. RGNX (not covered) reported top-line Phase 3 AFFINITY DUCHENNE

data for RGX-202. While overall microdystrophin expression appeared robust (71% via Western Blot at week 12), RGNX also

reported 2 SAEs (subacute myocarditis, liver injury). We see positive read through to SLDB. We view SGT-003 holding an easier

immune suppression regimen with preliminary microdystrophin data that looks at least on par. Pairing this wit the IMPACT

study already underway, and SLDB remains on "solid footing" with SGT-003.

**We will host SLDB management at an investor dinner in Boston on 5/19 -- please contact your Wedbush representative

for additional details.**

Sionna Therapeutics (SION)

Rating: OUTPERFORM, 12-Month Price Target: $53.00, Price: $42.77

[ICYMI] Revisiting SION Coverage Launch, Thoughts On Summer Data

The Wedbush View: Remain Outperform rated on SION. We initiated coverage of SION on 5/4/26 [LINK TO OUR INITIATION

REPORT]. While this occurred during the midst of 1Q26 reporting, investor feedback tilted positively with interest in SION's

upcoming readouts. Recall, SION will report two updates this summer: 1) top-line Phase 2a PreciSION data for SION-719 as an

add-on to Trikafta in CF patients, 2) top-line Phase 1 SION-451 data in healthy volunteers. We also checked in with SION CFO

Elena Ridloff this week. Herein, we revisit highlights from our discussion with CFO Ridloff and investor discussion topics we've

www.wedbush.com